MSD’s PD-1 inhibitor Keytruda has been approved by the FDA as a treatment for locally advanced unresectable or metastatic biliary tract cancer (BTC) in combination with chemotherapy, the first ...

Biliary tract cancer occurs in the bile ducts and gallbladder, with approximately 23,000 diagnoses in the US each year. Life expectancy is poor, with just 5% to 15% of patients expected to live ...

being held at 34 sites across the United States, has an estimated primary completion date of July 2025, and an estimated study completion date of December 2025, according to the trial information ...

The trial recruited 168 patients from 34 international sites living with unresectable ... of tovecimig in patients with advanced biliary tract cancer. We believe these findings highlight the ...

Topline data were announced from a phase 2/3 trial evaluating tovecimig in combination with paclitaxel in patients with unresectable advanced, metastatic or recurrent biliary tract cancers (BTC).

Biliary tract cancer affects approximately 23,000 patients annually in the United States, with the majority lacking an FDA-approved second-line treatment. The current trial’s results offer a ...

BOSTON - Compass Therapeutics, Inc. (NASDAQ:CMPX), a biopharmaceutical company specializing in oncology with a market capitalization of $263 million, announced positive results from its COMPANION-002 ...

“The IST complements our ongoing second-line Phase 2/3 study of tovecimig in patients with biliary tract cancer; importantly, we recently announced that tovecimig met the primary endpoint in our ...

The results of a clinical trial led by researchers at the University of Arizona Health Sciences and published in the Journal of Clinical Oncology showed that chemotherapy combining three different ...

Biliary tract cancer is estimated to affect approximately 23,000 patients annually in the United States. The study enrolled 168 adult patients. All patients were dosed with 80 mg/m2 of paclitaxel ...

Compass Therapeutics, Inc. (NASDAQ:CMPX) announced statistically significant topline data on Tuesday on the primary efficacy endpoint for COMPANION-002, the company’s ongoing Phase 2/3 trial of ...